Predictive and prognostic biomarkers in colorectal cancer

Abstract

Colorectal cancer is the third most common cancer and the second leading cause of cancer-related death in the United States. Three quarters of patients diagnosed with colorectal cancer will have early stage disease and despite surgical resection for curative intent, approximately 20%–25% of patients will recur with their disease within five years. The other 25% will present with advanced or metastatic disease and clinicians are faced with the challenge of choosing the most appropriate therapy for individual patients. Despite multiple treatment options which are now available and concomitant improvements in survival, advanced colorectal cancer remains universally fatal. The challenge for clinicians is to identify prognostic and predictive biomarkers that can assist in tailoring available treatments for an individual patient to improve clinical outcomes. This review will summarize current and future biomarkers in colorectal cancer and discuss their utility in managing patient care.

References

1 Aaltonen L A, Peltomäki P, Leach F S, Sistonen P, Pylkkänen L, Mecklin J P, Järvinen H, Powell S M, Jen J, Hamilton S R, . (1993). Clues to the pathogenesis of familial colorectal cancer. Science, 260(5109): 812–816

PMID

2 Amado R G, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D J, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson S D, Chang D D (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26(10): 1626–1634

PMID

3 André T, Bensmaine M A, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A (1999). Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol, 17(11): 3560–3568

PMID

4 Andreyev H J, Norman A R, Cunningham D, Oates J, Dix B R, Iacopetta B J, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes H M, Zietz C, Troungos C, Valavanis C, Yuen S T, Ho J W, Croke C T, O’Donoghue D P, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij A F, Arends J W, Andersen S N, Lövig T, Breivik J, Gaudernack G, Clausen O P, De Angelis P D, Meling G I, Rognum T O, Smith R, Goh H S, Font A, Rosell R, Sun X F, Zhang H, Benhattar J, Losi L, Lee J Q, Wang S T, Clarke P A, Bell S, Quirke P, Bubb V J, Piris J, Cruickshank N R, Morton D, Fox J C, Al-Mulla F, Lees N, Hall C N, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo V E, Finkelstein S D, Thebo J S, Senagore A J, Halter S A, Wadler S, Malik S, Krtolica K, Urosevic N (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer, 85(5): 692–696

PMID

5 Andreyev H J, Norman A R, Cunningham D, Oates J R, Clarke P A (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst, 90(9): 675–684

PMID

6 Arnaud J P, Koehl C, Adloff M (1980). Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum, 23(3): 141–144

PMID

7 Atkinson A J, Colburn W A, Degruttola V G,βDe Mets D L,βDowning DO G J,βHoth D F, Oates J A, Peck C C,βSchooley R T, Spilker B A,βWoodcock J,βZeger S L (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther, 69(3): 89–95

PMID

8 Augenlicht L H, Wahrman M Z, Halsey H, Anderson L, Taylor J, Lipkin M (1987). Expression of cloned sequences in biopsies of human colonic tissue and in colonic carcinoma cells induced to differentiate in vitro. Cancer Res, 47(22): 6017–6021

PMID

9 August D A, Sugarbaker P H, Ottow R T, Gianola F J, Schneider P D (1985). Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival. Ann Surg, 201(2): 210–218

PMID

10 Barrier A, Roser F, Boëlle P Y, Franc B, Tse C, Brault D, Lacaine F, Houry S, Callard P, Penna C, Debuire B, Flahault A, Dudoit S, Lemoine A (2007). Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene, 26(18): 2642–2648

PMID

11 Begent R H (1984). The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem, 21(Pt 4): 231–238

PMID

12 Bertagnolli M M, Niedzwiecki D, Compton C C, Hahn H P, Hall M, Damas B, Jewell S D, Mayer R J, Goldberg R M, Saltz L B, Warren R S, Redston M (2009). Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27(11): 1814–1821

PMID

13 Bertucci F, Salas S, Eysteries S, Nasser V, Finetti P, Ginestier C, Charafe-Jauffret E, Loriod B, Bachelart L, Montfort J, Victorero G, Viret F, Ollendorff V, Fert V, Giovaninni M, Delpero J R, Nguyen C, Viens P, Monges G, Birnbaum D, Houlgatte R (2004). Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene, 23(7): 1377–1391

PMID

14 Bokemeyer C, Bondarenko I, Hartmann J T, De Braud F G, Celik I, Koralewski P(2010). Biomarkers predictive for outcome on patients with metastatic colorectal cancer (mCRC) treated with first-line FOLFOX4 plus or minus cetuximab: Updated data from the OPUS study. Gastrointestinal Cancer Symposium, Abstract No. 428

15 Boland C R, Sato J, Appelman H D, Bresalier R S, Feinberg A P (1995). Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med, 1(9): 902–909

PMID

16 Buc E, Vartanian M D, Darcha C, Déchelotte P, Pezet D (2005). Guanylyl cyclase C as a reliable immunohistochemical marker and its ligand Escherichia coli heat-stable enterotoxin as a potential protein-delivering vehicle for colorectal cancer cells. Eur J Cancer, 41(11): 1618–1627

PMID

17 Carlson M R (2009). Previstage GCC colorectal cancer staging test: a new molecular test to identify lymph node metastases and provide more accurate information about the stage of patients with colorectal cancer. Mol Diagn Ther, 13(1): 11–14

PMID

18 Chapman M A, Buckley D, Henson D B, Armitage N C (1998). Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. Br J Cancer, 78(10): 1346–1349

PMID

19 Panel T M E (1996). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol, 14(10): 2843–2877

PMID

20 De Roock W, Jonker D J, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O’Callaghan C J, Khambata-Ford S, Zalcberg J R, Simes J, Karapetis C S, Bardelli A, Tejpar S (2010). Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA, 304: 1812–1820

21 Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26(35): 5705–5712

PMID

22 Douillard J Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J L, Rother M, Oliner K S, Wolf M, Gansert J (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28(31): 4697–4705

PMID

23 Fearon E R, Cho K R, Nigro J M, Kern S E, Simons J W, Ruppert J M, Hamilton S R, Preisinger A C, Thomas G, Kinzler K W, et (1990). Identification of a chromosome 18q gene that is altered in colorectal cancers. Science, 247(4938): 49–56

PMID

24 Fearon E R, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell, 61(5): 759–767

PMID

25 Fine B M, Amler L (2009). Predictive biomarkers in the development of oncology drugs: a therapeutic industry perspective. Clin Pharmacol Ther, 85(5): 535–538

PMID

26 Fletcher R H (1986). Carcinoembryonic antigen. Ann Intern Med, 104(1): 66–73

PMID

27 Frederiksen C M, Knudsen S, Laurberg S, Ørntoft T F (2003). Classification of Dukes’ B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol, 129(5): 263–271

PMID

28 Frick G S, Pitari G M, Weinberg D S, Hyslop T, Schulz S, Waldman S A (2005). Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Rev Mol Diagn, 5(5): 701–713

PMID

30 Gold P, Freedman S O (1965). Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med, 121(3): 439–462

PMID

31 Golub T R (2001). Genome-wide views of cancer. N Engl J Med, 344(8): 601–602

PMID

32 Golub T R, Slonim D K, Tamayo P, Huard C, Gaasenbeek M, Mesirov J P, Coller H, Loh M L, Downing J R, Caligiuri M A, Bloomfield C D, Lander E S (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286(5439): 531–537

PMID

33 Grady W M (2004). Genomic instability and colon cancer. Cancer Metastasis Rev, 23(1-2): 11–27

PMID

34 Gray R, Barnwell J, McConkey C, Hills R K, Williams N S, Kerr D J, Quasar Collaborative Group (2007). Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370(9604): 2020–2029

PMID

35 Greene F L P D, Balch C M, Page D L, Haller D G, Fleming I D, Morrow M, Fritz A G (2002). AJCC Cancer Staging Manual, 6th Edition. New York: Springer

36 Gryfe R, Kim H, Hsieh E T, Aronson M D, Holowaty E J, Bull S B, Redston M, Gallinger S (2000). Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med, 342(2): 69–77

PMID

37 Halling K C, French A J, McDonnell S K, Burgart L J, Schaid D J, Peterson B J, Moon-Tasson L, Mahoney M R, Sargent D J, O’Connell M J, Witzig T E, Farr G H Jr, Goldberg R M, Thibodeau S N (1999). Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst, 91(15): 1295–1303

PMID

38 Harrison L E, Guillem J G, Paty P, Cohen A M (1997). Preoperative carcinoembryonic antigen predicts outcomes in node-negative colon cancer patients: a multivariate analysis of 572 patients. J Am Coll Surg, 185(1): 55–59

PMID

39 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350(23): 2335–2342

PMID

40 Ionov Y, Peinado M A, Malkhosyan S, Shibata D, Perucho M (1993). Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature, 363(6429): 558–561

PMID

41 Ishizuka D, Shirai Y, Sakai Y, Hatakeyama K (2001). Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis, 16(1): 32–37

PMID

42 Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60(5): 277–300

PMID

43 Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola R M, Bujanda L, Reñé J M, Clofent J, Bessa X, Morillas J D, Nicolás-Pérez D, Pons E, Payá A, Alenda C, the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association (2009). The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer, 45(3): 365–373

PMID

44 Kallioniemi O P, Wagner U, Kononen J, Sauter G (2001). Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet, 10(7): 657–662

PMID

45 Karapetis C S, Khambata-Ford S, Jonker D J, O’Callaghan C J, Tu D, Tebbutt N C, Simes R J, Chalchal H, Shapiro J D, Robitaille S, Price T J, Shepherd L, Au H J, Langer C, Moore M J, Zalcberg J R (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 359(17): 1757–1765

PMID

46 Khine K, Smith D R, Goh H S (1994). High frequency of allelic deletion on chromosome 17p in advanced colorectal cancer. Cancer, 73(1): 28–35

PMID

47 Koch M, Kienle P, Kastrati D, Antolovic D, Schmidt J, Herfarth C, von Knebel Doeberitz M, Weitz J (2006). Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int J Cancer, 118(12): 3072–3077

PMID

48 Kohne C, Stroiakovski D, Chang-Chien C, Lim R, Pintér T, Bodoky G, Stroh C, Celik I, Rougier P, Van Cutsem E (2009). Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol, 27: 15s (Suppl; abstr 4068)

49 Kressner U, Bjørheim J, Westring S, Wahlberg S S, Påhlman L, Glimelius B, Lindmark G, Lindblom A, Børresen-Dale A L (1998). Ki-ras mutations and prognosis in colorectal cancer. Eur J Cancer, 34(4): 518–521

PMID

50 Lin Y H, Friederichs J, Black M A, Mages J, Rosenberg R, Guilford P J, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie A E, van Rij A, Yoon H S, McCall J L, Siewert J R, Holzmann B, Reeve A E (2007). Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res, 13: 498–507

51 Locker GY, Hamilton S, Harris J, Jessup J M, Kemeny N, Macdonald J S, Somerfield M R, Hayes D F, Bast R C Jr (2006). ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol, 24: 5313–5327

52 Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F (2009). KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer, 101(4): 715–721

PMID

53 McShane L M, Altman D G, Sauerbrei W, Taube S E, Gion M, Clark G M, the Statistics Subcommittee of NCI-EORTC Working Group on Cancer Diagnostics (2006a). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100(2): 229–235

PMID

54 McShane L M, Altman D G, Sauerbrei W, Taube S E, Gion M, Clark G M, the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2006b). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 28(2): 99–105

PMID

55 Mejia A, Waldman S A (2008). Previstage GCC test for staging patients with colorectal cancer. Expert Rev Mol Diagn, 8(5): 571–578

PMID

56 Minoo P, Moyer M P, Jass J R (2007). Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol, 212(2): 124–133

PMID

57 Nevins J R, Potti A (2007). Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet, 8(8): 601–609

PMID

58 Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T (2011). Gene expression profile can predict pathological response to preoperative chemoradio therapy in rectal cancer. Cancer Genomics Proteomics, 8(2): 87–92

PMID

59 O’Connell M J, Lavery I, Yothers G, Paik S, Clark-Langone K M, Lopatin M, Watson D, Baehner F L, Shak S, Baker J, Cowens J W, Wolmark N (2010). Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol, 28(25): 3937–3944

PMID

60 Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner G J, Meyerhardt J A, Fuchs C S (2009). Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol, 27(27): 4591–4598

PMID

61 Perou C M, Sørlie T, Eisen M B, van de Rijn M, Jeffrey S S, Rees C A, Pollack J R, Ross D T, Johnsen H, Akslen L A, Fluge O, Pergamenschikov A, Williams C, Zhu S X, Lønning P E, Børresen-Dale A L, Brown P O, Botstein D (2000). Molecular portraits of human breast tumours. Nature, 406(6797): 747–752

PMID

62 Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A (1998). Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum, 41(9): 1127–1133

PMID

63 Popat S, Houlston R S (2005). A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer, 41(14): 2060–2070

PMID

64 Popat S, Hubner R, Houlston R S (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23(3): 609–618

PMID

65 Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, Lambrechts D, Van Cutsem E, Tejpar S (2009). PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res, 15(9): 3184–3188

PMID

66 Ribic C M, Sargent D J, Moore M J, Thibodeau S N, French A J, Goldberg R M, Hamilton S R, Laurent-Puig P, Gryfe R, Shepherd L E, Tu D, Redston M, Gallinger S (2003). Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med, 349(3): 247–257

PMID

67 Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, Gascoyne R D, Muller-Hermelink H K, Smeland E B, Giltnane J M, Hurt E M, Zhao H, Averett L, Yang L, Wilson W H, Jaffe E S, Simon R, Klausner R D, Powell J, Duffey P L, Longo D L, Greiner T C, Weisenburger D D, Sanger W G, Dave B J, Lynch J C, Vose J, Armitage J O, Montserrat E, López-Guillermo A, Grogan T M, Miller T P, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt L M, the Lymphoma/Leukemia Molecular Profiling Project (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25): 1937–1947

PMID

68 Roth A D, Tejpar S, Yan P, Fiocca R, Dietrich D, Delorenzi M, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2009). Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. J Clin Oncol, 27: 15S (Suppl; abstr 4002)

69 Salazar R, Roepman P, Capella G, Moreno V, Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga J, Bruin S, Kerr D, Kuppen P, van de Velde C, Morreau H, Van Velthuysen L, Glas A M, Van’t Veer L J, Tollenaar R (2011). Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol, 29(1): 17–24

PMID

70 Saltz L B, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T S, Rivera F, Couture F, Sirzén F, Cassidy J (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26(12): 2013–2019

PMID

71 Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J,βSzabo S,βYan H, Gazdar A,β Powell S M, Riggins G J,βWillson J K V, Markowitz S, Kinzler K W, Vogelstein B,βVelculescu V E (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science, 304: 554

72 Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851–1857

PMID

73 Sargent D J, Marsoni S, Monges G, Thibodeau S N, Labianca R, Hamilton S R, French A J, Kabat B, Foster N R, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz J F, Sinicrope F, Gallinger S (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol, 28(20): 3219–3226

PMID

74 Shibata D, Reale M A, Lavin P, Silverman M, Fearon E R, Steele G Jr, Jessup J M, Loda M, Summerhayes I C (1996). The DCC protein and prognosis in colorectal cancer. N Engl J Med, 335(23): 1727–1732

PMID

75 Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, Gaasenbeek M, Angelo M, Reich M, Pinkus G S, Ray T S, Koval M A, Last K W, Norton A, Lister T A, Mesirov J, Neuberg D S, Lander E S, Aster J C, Golub T R (2002). Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 8(1): 68–74

PMID

76 Sugarbaker P H (1976). Carcinoembryonic antigen (CEA) assays in obstructive colorectal cancer. Ann Surg, 184(6): 752–757

PMID

77 Sun X F, Rütten S, Zhang H, Nordenskjöld B (1999). Expression of the deleted in colorectal cancer gene is related to prognosis in DNA diploid and low proliferative colorectal adenocarcinoma. J Clin Oncol, 17(6): 1745–1750

PMID

78 Tejpar S, Bosman F,Delorenzi M, Fiocca R, Yan P, Klingbiel D, Dietrich D, Van Cutsem E, Labianca R, Roth A (2009). Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol, 27:15S (Suppl; Abstr 4001)

79 Thompson J A, Grunert F, Zimmermann W (1991). Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal, 5(5): 344–366

PMID

80 Tol J, Nagtegaal I D, Punt C J (2009). BRAF mutation in metastatic colorectal cancer. N Engl J Med, 361(1): 98–99

PMID

81 Uen Y H, Lin S R, Wu D C, Su Y C, Wu J Y, Cheng T L, Chi C W, Wang J Y (2007). Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg, 246(6): 1040–1046

PMID

82 Vogelstein B, Fearon E R, Hamilton S R, Kern S E, Preisinger A C, Leppert M, Nakamura Y, White R, Smits A M, Bos J L (1988). Genetic alterations during colorectal-tumor development. N Engl J Med, 319(9): 525–532

PMID

83 Wanebo H J, Rao B, Pinsky C M, Hoffman R G, Stearns M, Schwartz M K, Oettgen H F (1978). Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med, 299(9): 448–451

PMID

84 Wang J Y, Lin S R, Wu D C, Lu C Y, Yu F J, Hsieh J S, Cheng T L, Koay L B, Uen Y H (2007). Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin Cancer Res, 13(8): 2406–2413

PMID

85 Wang Y, Jatkoe T, Zhang Y, Mutch M G, Talantov D, Jiang J, McLeod H L, Atkins D (2004). Gene expression profiles and molecular markers to predict recurrence of Dukes’B colon cancer. J Clin Oncol, 22: 1564–1571

86 Wichmann M W, Lau-Werner U, Müller C, Hornung H M, Stieber P, Schildberg F W, the Colorectal Cancer Study Group (2000). Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res, 20(6D): 4953–4955

PMID

87 Wiratkapun S, Kraemer M, Seow-Choen F, Ho Y H, Eu K W (2001). High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum, 44(2): 231–235

PMID

88 Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham D L, Fisher E R, Jones J, Glass A, Lerner H, Lawrence W, Prager D, Wexler M, Evans J, Cruz A, Dimitrov N, Jochimsen P (1988). Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst, 80(1): 30–36

PMID

89 Yeh C S, Wang J Y, Wu C H, Chong I W, Chung F Y, Wang Y H, Yu Y P, Lin S R (2006). Molecular detection of circulating cancer cells in the peripheral blood of patients with colorectal cancer by using membrane array with a multiple mRNA marker panel. Int J Oncol, 28(2): 411–420

PMID